Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4936957 | 1.00 | DUT (0.41) | DUT | |
| SCHEMBL1021376 | 0.86 | DUT (0.34) | DUT | |
| SCHEMBL11580466 | 0.81 | DUT (0.42) | DUT | |
| SCHEMBL26510570 | 0.80 | DUT (0.41) | DUT | |
| SCHEMBL20088142 | 0.80 | DUT (0.41) | DUT | |
| SCHEMBL30612911 | 0.80 | DUT (0.41) | DUT | |
| SCHEMBL29284186 | 0.80 | DUT (0.41) | DUT | |
| SCHEMBL25373236 | 0.78 | DUT (0.41) | DUT | |
| SCHEMBL2832489 | 0.78 | MEN1 (0.48) | DUT | |
| SCHEMBL680782 | 0.78 | DUT (0.41) | DUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240246992-A1 | MACROCYCLIC LRRK2 KINASE INHIBITORS | SERVIER LAB (FR) | 2024-07-25 | — | — | US | disclosed |
| EP-3426246-B1 | THIAZOLIDINONE COMPOUNDS AND USE THEREOF | NATIONAL HEALTH RES INST (TW) | 2024-05-01 | — | — | EP | disclosed |
| EP-4308570-A1 | MACROCYCLIC LRRK2 KINASE INHIBITORS | Les Laboratoires Servier (FR) | 2024-01-24 | — | — | EP | disclosed |
| CN-117425661-A | Macrocyclic LRRK2 kinase inhibitors | 法国施维雅药厂 | 2024-01-19 | — | — | CN | disclosed |
| WO-2023134629-A1 | NUCLEAR TRANSPORT REGULATOR AND USE THEREOF | 上海海雁医药科技有限公司 | 2023-07-20 | — | — | WO | disclosed |
| WO-2022194976-A1 | MACROCYCLIC LRRK2 KINASE INHIBITORS | LES LABORATOIRES SERVIER (FR) | 2022-09-22 | — | — | WO | disclosed |
| US-10544113-B2 | Thiazolidinone compounds and use thereof | NATIONAL HEALTH RESEARCH INSTITUTE (TW) | 2020-01-28 | — | — | US | disclosed |
| US-10544113-B2 | Thiazolidinone compounds and use thereof | NATIONAL HEALTH RESEARCH INSTITUTE (TW) | 2020-01-28 | — | — | US | disclosed |
| WO-2019243825-A1 | SMALL MOLECULE MODULATORS OF HUMAN STING, CONJUGATES AND THERAPEUTIC APPLICATIONS | CURADEV PHARMA LIMITED (GB) | 2019-12-26 | — | — | WO | disclosed |
| US-10280170-B2 | Substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazine derivatives and 5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a][1,4]diazepine derivatives as Ros1 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2019-05-07 | — | — | US | disclosed |
| WO-2009111337-A1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | IRM LLC (BM) | 2009-09-11 | — | — | WO | disclosed |
| US-7074819-B2 | Benzopyran or thiobenzopyran derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2006-07-11 | — | — | US | disclosed |
| US-20040102479-A1 | Novel benzopyran or thiobenzopyran derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA | 2004-05-27 | — | — | US | disclosed |
| US-6645951-B1 | Antiestrogens for treating breast cancer | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-11-11 | — | — | US | disclosed |
| EP-1087959-A1 | NOVEL BENZOPYRAN OR THIOBENZOPYRAN DERIVATIVES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2001-04-04 | — | — | EP | disclosed |
| WO-1999065893-A1 | NOVEL BENZOPYRAN OR THIOBENZOPYRAN DERIVATIVES | C & C RESEARCH LABORATORIES (KR) | 1999-12-23 | — | — | WO | disclosed |
| WO-1993012137-A1 | PHARMACEUTICAL COMPOSITIONS | BRITISH TECHNOLOGY GROUP LTD. (GB) | 1993-06-24 | — | — | WO | disclosed |
| US-5106860-A | Treating inflammation, circulatory disease, gastrointestinal ulceration, allergies | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1992-04-21 | — | — | US | disclosed |
| US-4992455-A | Cardiovascular disorders | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1991-02-12 | — | — | US | disclosed |
| EP-0292305-A1 | Novel thiazolidin-4-one derivatives and acid addition salts thereof | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1988-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102479-A1 | Novel benzopyran or thiobenzopyran derivatives | NR5A1, SHBG, ESR2 | DUT 3588/4885 |
| US-10544113-B2 | Thiazolidinone compounds and use thereof | OPRL1, OPRD1, OPRK1 | DUT 1512/4885 |
| US-20240246992-A1 | MACROCYCLIC LRRK2 KINASE INHIBITORS | LRRK2, PARK7, PINK1 | DUT 4065/4885 |
| US-10280170-B2 | Substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazine derivatives and 5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a][1,4]diazepine derivatives as Ros1 inhibitors | ROS1, NOX1, NOX5 | DUT 4009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.